{"title":"调节血脂的他汀类药物和纤维酸盐可降低精神分裂症患者的死亡率","authors":"","doi":"10.1002/pu.31199","DOIUrl":null,"url":null,"abstract":"<p>A nationwide cohort study conducted in Taiwan has found that lipid-modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all-cause and natural-cause mortality, the investigators reported. Study results were published online May 16, 2024, in <i>The British Journal of Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 9","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lipid-modifying statins, fibrates reduce mortality in schizophrenia patients\",\"authors\":\"\",\"doi\":\"10.1002/pu.31199\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A nationwide cohort study conducted in Taiwan has found that lipid-modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all-cause and natural-cause mortality, the investigators reported. Study results were published online May 16, 2024, in <i>The British Journal of Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"35 9\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31199\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lipid-modifying statins, fibrates reduce mortality in schizophrenia patients
A nationwide cohort study conducted in Taiwan has found that lipid-modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all-cause and natural-cause mortality, the investigators reported. Study results were published online May 16, 2024, in The British Journal of Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
